KLU156

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Novartis Pharma AG

Conditions

MalariaUncomplicated Plasmodium Falciparum Malaria

Phase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

RecruitingNCT05750628

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-01-23End: 2026-06-23Target: 327Updated: 2025-07-30

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

CompletedNCT07235033

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-01-23End: 2025-03-19Updated: 2026-03-13

Phase 3

Efficacy, safety and tolerability of KLU156 in adults and children = 5 kg body weight with uncomplicated P. falciparum malaria

RecruitingPACTR202303470809477

Novartis Pharma AGMalaria

Start: 2023-07-31Target: 1500Updated: 2026-01-27

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

CompletedNCT05842954

Novartis PharmaceuticalsUncomplicated Plasmodium Falciparum Malaria

Start: 2024-03-07End: 2025-11-25Updated: 2026-01-27

Related Papers

Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with <i>Plasmodium falciparum</i> Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study

The Journal of Clinical Pharmacology2024-09-294 citations